ARDX Ardelyx Inc.

-0.06  -2%
Previous Close 3.38
Open 3.38
Price To Book 1.8
Market Cap 208143913
Shares 62,599,673
Volume 51,536
Short Ratio
Av. Daily Volume 215,685

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 12, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 4Q 2019.
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3 data due 2H 2019.
Tenapanor - AMPLIFY
Adjunctive therapy to phosphate binders

Latest News

  1. If You Had Bought Ardelyx (NASDAQ:ARDX) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today
  2. East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?
  3. Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
  4. Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
  5. Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
  6. An Examination Of Ardelyx, Inc. (NASDAQ:ARDX)
  7. Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
  8. Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth
  9. Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
  10. Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount
  11. Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock?
  12. What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?
  13. Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
  14. Ardelyx: 3Q Earnings Snapshot
  15. Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
  16. Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
  17. Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
  18. Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
  19. How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?